58066-85-6
58066-85-6
Chemical Structure
Miltefosine
Synonym(s): HePC; Hexadecyl phosphocholine
- CAS No.: 58066-85-6
- Formula:C21H46NO4P
- Molecular Weight:407.57
IUPAC Name: hexadecyl (2-(trimethylammonio)ethyl) phosphate
InChIKey: PQLXHQMOHUQAKB-UHFFFAOYSA-N
SMILES: O=P(OCC[N+](C)(C)C)(OCCCCCCCCCCCCCCCC)[O-]
Biological Activity: Miltefosine is a broad spectrum antimicrobial, anti-leishmanial, phospholipid agent acting by inhibiting the PI3K/Akt activity[1][2][3][4]. Miltefosine is an inhibitor of CTP-phosphocholine cytidyltransferase (CCT)[5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Miltefosine | 99.92% | Miltefosine is a broad spectrum antimicrobial, anti-leishmanial, phospholipid agent acting by inhibiting the PI3K/Akt activity. Miltefosine is an inhibitor of CTP-phosphocholine cytidyltransferase (CCT). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Miltefosine (Standard) | 99.98% | Miltefosine (Standard) is the analytical standard of Miltefosine. This product is intended for research and analytical applications. Miltefosine is a broad spectrum antimicrobial, anti-leishmanial, phospholipid agent acting by inhibiting the PI3K/Akt activity. Miltefosine is an inhibitor of CTP-phosphocholine cytidyltransferase (CCT). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Miltefosine-d4 | Miltefosine-d4 (HePC-d4) is deuterium labeled Miltefosine. Miltefosine is a broad spectrum antimicrobial, anti-leishmanial, phospholipid agent acting by inhibiting the PI3K/Akt activity. Miltefosine is an inhibitor of CTP-phosphocholine cytidyltransferase (CCT). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Chugh P, et al. Akt inhibitors as an HIV-1 infected macrophage-specific anti-viral therapy. Retrovirology. 2008 Jan 31;5:11 [Content Brief]
- [2]. Uberall F, et al. Hexadecylphosphocholine inhibits inositol phosphate formation and protein kinase C activity. Cancer Res. 1991 Feb 1;51(3):807-12. [Content Brief]
- [3]. Bhatt AP, et al. Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas. Blood. 2010 Jun 3;115(22):4455-63. [Content Brief]
- [4]. Eissa MM, et al. Miltefosine Lipid Nanocapsules for Single Dose Oral Treatment of Schistosomiasis Mansoni: A Preclinical Study. PLoS One. 2015 Nov 17;10(11):e0141788 [Content Brief]
- [5]. de Freitas-Junior PR, et al. Effects of miltefosine on the proliferation, ultrastructure, and phospholipid composition of Angomonas deanei, a trypanosomatid protozoan that harbors a symbiotic bacterium. FEMS Microbiol Lett. 2012 Aug;333(2):129-37. [Content Brief]
